Axsome Therapeutics Reports Strong Q2 2026 Growth on Auvelity Expansion — Axsome Therapeutics, Inc.

Event summary

Q2 2026 net product revenue of $218.4M, up 46% YoY, driven by Auvelity's 51% growth to $180.3M.
Auvelity launched for Alzheimer’s agitation in June 2026; new-to-brand prescriptions surged 126% post-launch.
FDA accepted AXS-12 NDA submission with PDUFA target action date of May 1, 2027.
FOCUS-2 and FOCUS-3 Phase 3 trials for solriamfetol in pediatric ADHD initiated.
Cash position at $319.9M as of June 30, 2026.

The big picture

Axsome’s Q2 results highlight its strategic focus on expanding Auvelity’s reach in high-unmet-need CNS indications, particularly Alzheimer’s agitation. The company’s robust pipeline—spanning ADHD, fibromyalgia, and narcolepsy—positions it to capitalize on regulatory and commercial milestones over the next 18 months. With cash runway extending into profitability, execution risks now center on maintaining payer coverage and trial success rates.

What we're watching

Commercial Execution: Whether Axsome can sustain Auvelity’s momentum in Alzheimer’s agitation and MDD amid payer coverage challenges.
Pipeline Progress: The pace of solriamfetol trial results, particularly the ENGAGE study for binge eating disorder due in Q4 2026.
Regulatory Milestones: How AXS-12’s FDA review progresses toward the May 2027 PDUFA date and its potential impact on narcolepsy treatment.